Table 2. Multivariate Analysis of Clopidogrel Response as Measured by Adenosine Diphosphate–Stimulated Platelet Aggregation in PAPI Study Participants (n = 429).
| Characteristic | β (SE) | P Valuea | Variance of Significant Predictors, % |
|---|---|---|---|
| Age | 0.19 (0.04) | <.001 | 3.8 |
| Sex | 1.73 (1.15)b | .13 | |
| Body mass index | 0.35 (0.12) | .005 | 2.3 |
| Lipids | |||
| Total cholesterol | 0.01 (0.01) | .27 | |
| HDL-C | −0.08 (0.04) | .04 | 1.0 |
| LDL-C | 0.02 (0.01) | .17 | |
| Log triglycerides | 0.03 (0.01) | .01 | 1.3 |
| Blood pressure | |||
| Systolic | 0.0 (0.05) | .21 | |
| Diastolic | 0.07 (0.08) | .42 |
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAPI, Pharmacogenomics of Anti-Platelet Intervention.
a
Adjusted for age, sex, and preclopidogrel adenosine diphosphate (20 μmol/L)–stimulated platelet aggregation; age adjusted for sex and preclopidogrel platelet aggregation; sex adjusted for age and preclopidogrel platelet aggregation.
b
Indicates that women tend to respond less well than men.